Answers are grounded in this paper and cite their sources.
Hypothesis-generating for H. pylori eradication in aspirin users; leaves open cardiovascular outcome modification in prospective trials.
We thank Yu et al published in the World Journal of Gastroenterology, for their commentary on our study of Helicobacter pylori eradication in chronic low-dose aspirin users.They commend our real-world cohort design and histopathological integration.Their suggestions focus on optimizing eradication protocols, refining mechanistic interpretation of cardiovascular outcomes, and targeting surveillance strategies.We address each point below.Our eradication rate of 51.9% reflects real-world effectiveness in a high-resistance region and compares favorably with local data.Our composite cardiovascular endpoint was pre-specified and clinically actionable, and our findings remained robust after adjustment for baseline multivessel coronary artery disease and in an E-value sensitivity analysis.Our study was not designed to test the specific mechanistic pathways proposed, and we welcome future research incorporating serial biomarkers and aspirin dosage stratification.Our findings remain hypothesisgenerating, and we provide a foundation for prospective studies.
No takes yet. Share an insight, caveat, or question.
Amira AA Othman (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: